Par Pharmaceutical announced the launch of Khedezla (desvenlafaxine) extended-release (ER) tablets for the treatment of major depressive disorder.

RELATED: Psychiatric Disorders Resource Center

Desvenlafaxine is a potent and selective serotonin and norepinephrine reuptake inhibitor (SNRI). The exact mechanism of the antidepressant action of Khedezla is unknown, but is thought to be related to the potentiation of serotonin and norepinephrine in the central nervous system, through inhibition of their reuptake.

The new drug application included comparative bioequivalence testing against Pristiq (desvenlafaxine; Pfizer) extended-release tablets.

Khedezla is available in 50mg and 100mg strength extended-release tablets, in 30- and 90-count bottles.

For more information call (800) 828-9393 or visit